We are delighted to be collaborating with Reykjavik-based EpiEndo Pharmaceuticals on its First-in-Human Clinical trial of its Lead Compound, EP395, for Chronic Inflammatory Airway Disease.

The trial is led by our Medical Director, Professor Dave Singh, Professor of Respiratory Pharmacology at the University of Manchester.